Blood:Fc-修饰型抗PF4-NET复合物单克隆抗体KKO明显改善脓毒症预后

2019-11-15 QQY MedSci原创

脓毒症是由感染引起的全身炎症反应综合征,特征是炎症导致多器官系统功能障碍。发病率和病死率高,需要改善其治疗方法。中性粒细胞在脓毒症过程中具有至关重要的作用,它释放由组蛋白和有毒抗菌蛋白组成的胞外中性粒细胞陷阱(NETs)来捕捉病原体,但与此同时也会损伤宿主组织。发病时,患者往往已有很重的NET负荷,导致多器官受损。因此,发病时再予以抑制NET释放的干预措施,在预防NET相关损伤方面可能是无效的。加

中心点:

PF4通过稳定NETs和增强NET介导的微生物诱捕来改善脓毒症的预后

KKO,一种Fc修饰的HIT样抗体,可进一步加强PF4在脓毒症中的有利作用

摘要:

脓毒症是由感染引起的全身炎症反应综合征,特征是炎症导致多器官系统功能障碍。发病率和病死率高,需要改善其治疗方法。中性粒细胞在脓毒症过程中具有至关重要的作用,它释放由组蛋白和有毒抗菌蛋白组成的胞外中性粒细胞陷阱(NETs)来捕捉病原体,但与此同时也会损伤宿主组织。发病时,患者往往已有很重的NET负荷,导致多器官受损。因此,发病时再予以抑制NET释放的干预措施,在预防NET相关损伤方面可能是无效的。加强NET降解可能会释放捕获的细菌和有毒的NET降解产物(NDPs),而且可能也没有多少治疗效果。

Gollomp等人认为稳定NETs和隔离NDPs或可加强脓毒症的治疗,并经研究发现血小板因子4(PF4),一种血小板相关的趋化因子,可结合NETs,并使其更为紧密,从而增强其对脱氧核糖核酸酶I的抵抗力。此外,研究人员还发现PF4可增强NET介导的细菌捕获,减少NDPs的释放,提高脓毒症小鼠模型的预后。

KKO,一种与PF4-NET复合物结合的单克隆抗体,可进一步增强对脱氧核糖核酸酶的抵抗力。但该抗体的Fc段可激活免疫反应,增加血栓风险,抵消对脓毒症的任何保护作用。

因此,研究人员开发了一种Fc-修饰的KKO,不会诱导任何负性预后。采用这种抗体治疗可放大PF4的效应,减少NDP释放和细菌扩散,提高脓毒症小鼠模型的存活。综上所述,本研究表明该新型的靶向NET的治疗方法或可用于改善脓毒症患者预后。

原始出处:

Kandace Gollomp, et al.Understanding how Fc-modification transforms a pathogenic HIT-like monoclonal antibody into a novel treatment for sepsis.blood.2019002329.https://doi.org/10.1182/blood.2019002329

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1660206, encodeId=4329166020695, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Aug 17 14:40:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702902, encodeId=7c601e0290299, content=<a href='/topic/show?id=6d5414113d5' target=_blank style='color:#2F92EE;'>#PF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14113, encryptionId=6d5414113d5, topicName=PF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217830458022, createdName=sunmin0229, createdTime=Sat Oct 24 10:40:00 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910649, encodeId=e52d19106495e, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 30 09:40:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734190, encodeId=9d521e34190eb, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Oct 03 15:40:00 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569381, encodeId=9b9a156938143, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Nov 17 11:40:00 CST 2019, time=2019-11-17, status=1, ipAttribution=)]
    2020-08-17 aids221
  2. [GetPortalCommentsPageByObjectIdResponse(id=1660206, encodeId=4329166020695, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Aug 17 14:40:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702902, encodeId=7c601e0290299, content=<a href='/topic/show?id=6d5414113d5' target=_blank style='color:#2F92EE;'>#PF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14113, encryptionId=6d5414113d5, topicName=PF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217830458022, createdName=sunmin0229, createdTime=Sat Oct 24 10:40:00 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910649, encodeId=e52d19106495e, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 30 09:40:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734190, encodeId=9d521e34190eb, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Oct 03 15:40:00 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569381, encodeId=9b9a156938143, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Nov 17 11:40:00 CST 2019, time=2019-11-17, status=1, ipAttribution=)]
    2020-10-24 sunmin0229
  3. [GetPortalCommentsPageByObjectIdResponse(id=1660206, encodeId=4329166020695, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Aug 17 14:40:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702902, encodeId=7c601e0290299, content=<a href='/topic/show?id=6d5414113d5' target=_blank style='color:#2F92EE;'>#PF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14113, encryptionId=6d5414113d5, topicName=PF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217830458022, createdName=sunmin0229, createdTime=Sat Oct 24 10:40:00 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910649, encodeId=e52d19106495e, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 30 09:40:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734190, encodeId=9d521e34190eb, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Oct 03 15:40:00 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569381, encodeId=9b9a156938143, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Nov 17 11:40:00 CST 2019, time=2019-11-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1660206, encodeId=4329166020695, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Aug 17 14:40:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702902, encodeId=7c601e0290299, content=<a href='/topic/show?id=6d5414113d5' target=_blank style='color:#2F92EE;'>#PF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14113, encryptionId=6d5414113d5, topicName=PF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217830458022, createdName=sunmin0229, createdTime=Sat Oct 24 10:40:00 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910649, encodeId=e52d19106495e, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 30 09:40:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734190, encodeId=9d521e34190eb, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Oct 03 15:40:00 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569381, encodeId=9b9a156938143, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Nov 17 11:40:00 CST 2019, time=2019-11-17, status=1, ipAttribution=)]
    2020-10-03 canlab
  5. [GetPortalCommentsPageByObjectIdResponse(id=1660206, encodeId=4329166020695, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Mon Aug 17 14:40:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702902, encodeId=7c601e0290299, content=<a href='/topic/show?id=6d5414113d5' target=_blank style='color:#2F92EE;'>#PF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14113, encryptionId=6d5414113d5, topicName=PF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=217830458022, createdName=sunmin0229, createdTime=Sat Oct 24 10:40:00 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910649, encodeId=e52d19106495e, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Apr 30 09:40:00 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734190, encodeId=9d521e34190eb, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Oct 03 15:40:00 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569381, encodeId=9b9a156938143, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sun Nov 17 11:40:00 CST 2019, time=2019-11-17, status=1, ipAttribution=)]
    2019-11-17 zhangyxzsh

相关资讯

Clinica Chimica Acta:采用新型LC-MS/MS法测定脓毒症休克时血浆缓激肽浓度

缓激肽是炎症和血管通透性的重要介质,在感染性休克的发生过程中可能发挥重要作用。然而,采用免疫学方法测定缓激肽可能受到干扰,且缺乏特异性。因此本研究建立了血浆缓激肽的液相色谱 · 2019-08-06

-->

Crit Care Med:脓毒症与微血管脑损伤的关系

由此可见,通过微血管梗塞评估,脓毒症与中度至重度血管脑损伤特异性相关。对于大脑皮质内的微小梗塞,这种关联更强,那些经历严重脓毒症住院治疗的患者在调整分析中有中度至重度大脑皮质损伤证据的可能性超过两倍。需要进一步研究以确定脓毒症和微小梗塞之间的相关机制。

Blood:脓毒症时,血小板的转录本和翻译组均发生明显改变

越来越多的人认识到血小板在脓毒症的病理生理过程中具有重要的作用,但这一点目前还没有明确的定义。脓毒症是否会改变人类血小板的转录和翻译尚未明确。近日,《Blood》杂志上发表一篇文章,研究人员利用RNA测序和核糖体足迹分析来研究脓毒症患者和健康献血者的血小板的转录组和翻译组。研究人员从脓毒症患者的血小板中共鉴定出1806个表达具有显著差异的转录本(FDR < 0.05)。在脓毒症过程中,血小板

Crit Care:发病前β受体阻滞剂暴露与脓毒症死亡率之间的关联

由此可见,该系统评价表明败血症发病前的β受体阻滞剂暴露与死亡率降低有关。没有足够的数据进行真正的荟萃分析,目前尚不清楚死亡率的明显降低是否可归因于过量儿茶酚胺的减少。

Eur Respir J:脓毒症患者的生存率与外周血白细胞端粒长度有关

在危重病患者,特别是脓毒症患者中,较短的PBL-TL与较差的生存率和更严重的ARDS密切相关。这些结果表明端粒功能障碍可能导致危重病患者较差的预后。

美国FDA授予Nangibotide治疗感染性休克的快速通道资格

Inotrem是一家专门从事慢性炎症综合征免疫治疗的生物技术公司,近日宣布美国FDA已授予Nangibotide快速通道资格,用于治疗感染性休克。Nangibotide是一种TREM-1抑制剂肽,能够恢复适当的炎症反应,并改善血管功能和脓毒症后的存活。